Gray matter volume in women with the BRCA mutation with and without ovarian removal: evidence for increased risk of late-life Alzheimer's disease or dementia
- 1Psychology, University of Toronto, Toronto, ON, Canada.
- 2Department of Acute Internal Medicine and Geriatrics, and Department of Health, Medicine and Caring Sciences, Division of Prevention, Rehabilitation and Community Medicine, Linköping University, Linköping, Sweden.
- 3Thematic Studies, Linköping University, Sweden.
- 4Department of Oncology in Linköping and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
- 5Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
- 6Department of Clinical Immunology and Transfusion Medicine, and Department of Biomedical and Clinical Sciences, Linköping University, Sweden.
- 7Department of Obstetrics and Gynecology and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
- 0Psychology, University of Toronto, Toronto, ON, Canada.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Early ovarian removal in BRCA mutation carriers may increase dementia risk. Post-surgery estradiol therapy appears to mitigate gray matter loss, suggesting potential neuroprotection.
Area Of Science
- Neuroscience
- Oncology
- Endocrinology
Background
- Ovarian removal before natural menopause is linked to higher dementia risk, possibly due to lost estradiol.
- Women with BRCA mutations undergo oophorectomy to reduce cancer risk, but neurological effects are understudied.
- Previous studies suggest cortical thinning and cognitive changes after oophorectomy.
Purpose Of The Study
- To investigate whole-brain gray matter volume differences in women with BRCA mutations before and after oophorectomy.
- To compare neurological effects of oophorectomy with and without estradiol hormone therapy.
- To assess the impact of BRCA mutations and early oophorectomy on brain structure.
Main Methods
- Cross-sectional study using high-resolution quantitative MRI.
- Compared gray matter volume in four groups: BRCA-positive pre-oophorectomy, post-oophorectomy without hormone therapy, post-oophorectomy with hormone therapy, and age-matched controls.
- Analyzed whole-brain gray matter differences.
Main Results
- Women with BRCA mutations (pre- and post-oophorectomy) showed significantly lower gray matter volume in medial temporal and frontal lobes.
- Post-oophorectomy estradiol therapy group had fewer gray matter volume reductions compared to controls.
- All BRCA mutation groups exhibited higher gray matter volume than controls, indicating plasticity.
Conclusions
- BRCA mutations and early oophorectomy may contribute to increased late-life dementia risk.
- Post-surgical estradiol therapy may help reduce gray matter loss in BRCA carriers who undergo oophorectomy.
- Findings support the role of estradiol in maintaining brain structure and potentially mitigating dementia risk.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
02:07
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
01:26
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

